Evidence map›Paper›PMID 35197558›Full record

ArticleProstate cancer and prostatic diseases2023

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.

Bobby Shayegan, Christopher J D Wallis, Robert J Hamilton, Scott C Morgan, Ilinas Cagiannos, Naveen S Basappa, Cristiano Ferrario, Geoffrey T Gotto, Ricardo Fernandes, Soumyajit Roy and 8 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05471427 (Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05471427 completednot on this map

Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)

TypeobservationalSponsorAzienda Ospedaliero-Universitaria CareggiRan2020 to 2022Enrolled118ConditionsElderly Patients, Metastatic Prostate CancerArmsTaxane chemotherapy
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 2 countries.

Bobby ShayeganSt. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Christopher J D WallisMount Sinai Hospital, Toronto, ON, Canada. wallis.cjd@gmail.com.ORCID http://orcid.org/0000-0002-5990-4026
Robert J HamiltonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Scott C MorganThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-6568-3346
Ilinas CagiannosThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Cristiano FerrarioSegal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Geoffrey T GottoSouthern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
Ricardo FernandesLondon Regional Cancer Program, London, ON, Canada.
Soumyajit RoyRadiation Oncology, Rush University Cancer Center, Chicago, IL, USA.
Krista L NoonanBC Cancer Agency, University of British Columbia, Surrey, BC, Canada.
Tamim NiaziJewish General Hospital, McGill University, Montreal, QC, Canada.
Sebastien J HotteJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Fred SaadCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-2986-5617
Huong HewJanssen Inc., Toronto, ON, Canada.
Laura Park-WyllieJanssen Inc., Toronto, ON, Canada.
Katherine F Y ChanJanssen Inc., Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4238-0921
Shawn MaloneThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
University of Ottawa · CAJewish General Hospital · CABC Cancer Agency · CACancer Care Ontario · CACentre Hospitalier de l’Université de Montréal · CAJuravinski Cancer Centre · CAMount Sinai Hospital · CARush University · USSt. Joseph’s Healthcare Hamilton · CAUniversity of Alberta · CAUniversity of Calgary · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe adoption of docetaxel for systemic treatment of metastatic prostate cancer (PCa), in both castration-sensitive (mCSPC) and castration-resistant (mCRPC) settings, is poorly understood. This study examined the real-world utilization of docetaxel in these patients and their outcomes.

methodsA retrospective population-based study used administrative data from Ontario, Canada, to identify men aged ≥66 years who were diagnosed with de novo mCSPC or mCRPC between 2014 and 2019 and received docetaxel. The study assessed treatment tolerability and toxicity, and survival in both cohorts. Descriptive and comparative statistical analysis were conducted.

resultsThe study identified 11.2% (399/3556) and 13.2% (203/1534) patients diagnosed with de novo mCSPC and with mCRPC who received docetaxel respectively. The median age in both cohorts was 72 years (IQR: 68-76). Overall, 43.9% (n = 175) patients with de novo mCSPC and 52.1% (n = 85) with mCRPC completed ≥6 cycles of docetaxel. Over two-fifth also needed dose adjustments in both cohorts. Hospitalization or emergency department visit for febrile neutropenia were noted in 15.8% (n = 63) of de novo mCSPC patients and similarly in 19% (n = 31) of mCRPC cohort. The median survival of PCa patients who completed ≥6 cycles of docetaxel was significantly longer relative to those who completed <4 cycles: 32.7 vs. 23.5 months (p < 0.001) for mCSPC and 20.5 vs. 10.7 (p = 0.012) for mCRPC respectively.

conclusionsIn this population-based study of elderly patients with metastatic PCa, treatment with docetaxel was associated with poor tolerability and higher toxicity compared with clinical trials. Receipt of limited cycles and reduced overall dose of docetaxel were associated with inferior overall survival.

Indexed as

Prostatic Neoplasms, Castration-ResistantAgedCohort StudiesDocetaxelHumansMaleOntarioRetrospective StudiesTreatment OutcomeDocetaxel

Identifiers

PMID35197558
OpenAlexW4213301220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.